

RespireRx Pharmaceuticals

09:49 17 Mar 2022

RespireRx Pharmaceuticals notes publication of paper on newest GABAkinine analog which protects against seizures and lethality

RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has noted the publication of a paper detailing the company's newest candidate D5-KRM-II-81, which is a so-called GABAkinine - a type of medicine which enhances the inhibitory neurotransmitter in the brain.

This latest asset is a structurally related analog to KRM-II-81, which, as previously reported, RespireRX's EndeavourRx business unit is advancing for the treatment of epilepsy and chronic pain.

D5-KRM-II-81 is being evaluated by EndeavourRx as a "potent, and orally bioavailable backup that will be used as needed as KRM-II-81 enters its clinical development," the company said in a statement.

"Doses of D5- KRM-II-81 as low as 2 mg/kg provided enduring exposure of plasma and brain of rats after oral administration. Importantly, like KRM-II-81, D5-KRM-II-81 completely prevented clonic seizures, tonic seizures, and lethality induced by the GABA receptor antagonist chemoconvulsant pentylenetetrazol.

READ: RespireRx Pharmaceuticals notes publication of paper on GABAkinine KRM-II-81, which it is advancing for epilepsy and pain

"Experimental work in human epileptic brain tissue from patients that are resistant to standard of care antiepileptic medicines is ongoing," the firm added.

The latest paper is entitled "Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the γ -3-selective GABAkinine KRM-II-81 in Biopharmaceutics and Drug Disposition."

A team of authors was behind the article, led by Dr Jeffrey M. Witkin, a senior research fellow at RespireRx, with contributions from academic collaborators from various universities and Arnold Lipka, who is RespireRx's executive chairman, interim president, interim CEO and chief scientific officer.

Dr Witkin said: "The antiepileptic potential discovered for D5-KRM-II-81 allows this new orally-bioavailable analog to assist with our drug development efforts in pharmaco-resistant epilepsy and pain. Given the large unmet medical need in both of these areas, we are excited to have this new structural analog in our hands."

RespireRx is focused on treatments where there is poorly or unmet need, based on modifying neurotransmission (brain signaling), which have advantages to currently available drugs, if there are any.

These include for obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD), epilepsy, chronic pain and spinal cord injury (SCI).

Contact the author at giles@proactiveinvestors.com

Price: 0.01135

Market Cap: \$1.08 m

1 Year Share Price Graph



March 2021 September 2021 March 2022

Share Information

Code: RSPI

Listing: OTCQB

52 week High Low
0.079 0.006

Sector: Pharma & Biotech

Website: respirerx.com

Company Synopsis:

RespireRx Pharmaceuticals Inc is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of RespireRx Pharmaceuticals named herein, including the promotion by the Company of RespireRx Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual cash compensation of typically up to \$25,000.